May 7, 2026
For roughly forty years, oncologists have treated pancreatic cancer with the grim arithmetic of months gained, not years. A new drug called daraxonrasib appears ready to rewrite that math. In late-stage trial data, patients who added it to chemotherapy lived roughly twice as long as those on chemo alone – […]
